Morgan Stanley initiated coverage of MapLight Therapeutics (MPLT) with an Overweight rating and $34 price target The company’s lead asset, ML007-C-MA, has “best in class potential” in the greater than $20B market for antipsychotics, the analyst tells investors in a research note. The firm says approved antipsychotics are all very similar, with high switch rates, positioning novel drug mechanisms to gain market share.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MPLT: